EUVIMEDEUVIMED entdecken
Open Access

Efficacy of Apatinib plus Temozolomide in Treating Recurrent Malignant Brain Glioma

Guoquan Li, Tao Hu, Yangwu Hu, Hailiang Shi, Ling Li, Gang Xiong

African Health Sciences · 2025

DOI: 10.4314/ahs.v25i2.17 ↗

Kurz gefasst

Fachartikel in der Zeitschrift African Health Sciences, 2025. Verfasst von Guoquan Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Wuhan Jiangxia District First People's Hospital, Wuhan, China. Hauptthemen laut MEDLINE: Temozolomide, Glioma, Brain Neoplasms, Pyridines. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To evaluate the efficacy and safety of apatinib plus tenozolomide in the treatment of recurrent malignant brain glioma.

Methods

A retrospective analysis of 108 patients with recurrent malignant brain glioma was conducted at our hospital. Out of these, 54 patients received apatinib plus tenozolomide as combination therapy (Combination group) while the remaining 54 were treated with temozolomide alone (Control group). Clinical data was collected and analyzed to compare the treatment efficacy and incidence of adverse reactions between the two groups. Additionally, patient survival and progression-free survival (PFS) were monitored and recorded.

Results

The study evaluated the efficacy of a treatment among patients who completed it. The Combination group had a higher objective response rate (ORR) and disease control rate (DCR) compared to the Control group. Treatment-related adverse reactions were mostly grade I-II and improved with symptomatic treatment. The Combination group had higher incidence rates of hypertension, proteinuria, and hand-foot syndrome. Follow-up results showed that the Combination group had a significantly better overall survival (OS) and progression-free survival (PFS) than the Control group.

Conclusion

Compared with temozolomide alone, apatinib plus tenozolomide can significantly improve the clinical efficacy in treating recurrent malignant brain glioma, prolong the survival of patients and produce tolerable adverse reactions. Keywords: Apatinib; temozolomide; recurrence; glioma; efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideGliomaBrain NeoplasmsPyridinesNeoplasm Recurrence, LocalAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic AgentsHumansFemaleMaleRetrospective StudiesMiddle AgedAdultTreatment OutcomeAgedProgression-Free Survival

Stichwörter der Autor:innen

apatinibefficacygliomarecurrencetemozolomide

Substanzen

TemozolomideapatinibPyridinesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Neurosurgery, Wuhan Jiangxia District First People's Hospital, Wuhan, China.

Zitieren

APA

Li, G., Hu, T., Hu, Y., Shi, H., Li, L., & Xiong, G. (2025). Efficacy of Apatinib plus Temozolomide in Treating Recurrent Malignant Brain Glioma. African Health Sciences. https://doi.org/10.4314/ahs.v25i2.17

Vancouver

Li G, Hu T, Hu Y, Shi H, Li L, Xiong G. Efficacy of Apatinib plus Temozolomide in Treating Recurrent Malignant Brain Glioma. African Health Sciences. 2025. doi:10.4314/ahs.v25i2.17

BibTeX
@article{Li2025,
  author = {Li, Guoquan and Hu, Tao and Hu, Yangwu and Shi, Hailiang and Li, Ling and Xiong, Gang},
  title = {Efficacy of Apatinib plus Temozolomide in Treating Recurrent Malignant Brain Glioma},
  journal = {African Health Sciences},
  year = {2025},
  doi = {10.4314/ahs.v25i2.17}
}
Kostenlos starten →